Status: Recruiting
PEP-CMV + Nivolumab for Newly Diagnosed Diffuse Midline Glioma/High-grade Glioma and Recurrent Diffuse Midline Glioma/High-grade Glioma, Medulloblastoma, and Ependymoma
This is a multisite, phase I/II clinical trial in children and young adults with newly-diagnosed high-grade glioma (HGG), diffuse midline glioma (DMG) and recurrent HGG/DMG, Medulloblastoma (MB), or ependymoma (EPN) to determine the safety, immunogenicity, and efficacy of a CMV-directed peptide vaccine plus checkpoint blockade.
Participants needed: 68
Trial details
Phase: Phase 1, Phase 2Age: 4-25Biological sex: AllType: InterventionalSponsor: Washington University School of MedicineUpdated: Jun 17, 2026Locations: 3
Eligibility criteria
Patients must be ≥4 and ≤25 years of age (inclusive) at the time of study enroll... [+39]
Pregnant or breast-feeding women will not be entered on this study due to known... [+11]